Pediatric usage of Omalizumab: A promising one.
Pediatric usage of Omalizumab: A promising one.
复制标题
DOI：
10.1016/j.waojou.2021.100614
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Ye L
中科院分区：
文献类型：
--
作者：
Yu L;Zhang H;Pan J;Ye L
过敏性疾病和相关疾病对儿科人群有很大的流行病学影响。小分子药物传统上用于控制疾病。奥马珠单抗是第一个用于儿童过敏的单克隆抗体药物，并显示出巨大的前景。它与游离IgE结合并阻止其与IgE受体结合，从而中断IgE依赖性过敏性炎症级联反应。大量的数据表明，它的有效性和良好的耐受性，患者，包括儿童。然而，该药物仅被批准用于过敏性哮喘和慢性自发性荨麻疹（CSU），尽管在临床试验中探索了其他应用。本文综述了奥马珠单抗在儿童过敏性疾病中的应用，重点介绍了奥马珠单抗在哮喘和CSU以外的过敏性疾病中的应用，包括过敏性鼻炎、过敏性支气管肺曲霉病、春季角结膜炎、食物过敏和特应性皮炎。此外，我们强调了未满足的需求和抗IgE治疗的争议问题。奥马珠单抗，第一个单克隆抗体为基础的药物用于儿童过敏，显示了巨大的希望。奥马珠单抗可有效缓解几乎所有儿童的过敏及相关疾病（哮喘和CSU除外）相关症状。在过敏性疾病和相关疾病中，抗IgE治疗存在未满足的需求和有争议的问题。
Allergic and related diseases have a substantial epidemiological impact on the pediatric population. Small molecule-based medicines have been traditionally used to manage the diseases. Omalizumab is the first monoclonal antibody-based medicine used in children's allergy and shows great promises. It binds to free IgE and prevents it from binding to IgE receptors, thus interrupting the IgE-dependent allergic inflammatory cascade. Vast amounts of data demonstrate its effectiveness and well tolerance by patients, including the children. However, the drug was only approved to use in allergic asthma and chronic spontaneous urticaria (CSU), though other applications were explored in clinical trials. In this review, we summarized current pediatric applications of omalizumab in allergic diseases, focusing on its usages beyond asthma and CSU, including allergic rhinitis, allergic bronchopulmonary aspergillosis, vernal keratoconjunctivitis, food allergy and atopic dermatitis. In addition, we highlighted the unmet needs and controversial issues of anti-IgE therapy. Omalizumab, the first monoclonal antibody-based medicine used in children's allergy, shows great promise. Omalizumab is effective in relieving symptoms associated with almost every children's allergic and related diseases beyond asthma and CSU. There are unmet needs and controversial issues of anti-IgE therapy in allergic and related diseases.
登录
查看更多内容
影响因子：
4.4
作者：
Chan MA;Gigliotti NM;Dotson AL;Rosenwasser LJ
通讯作者：
Rosenwasser LJ
影响因子：
26.1
作者：
Chan, Susan;Cornelius, Victoria;Lack, Gideon
通讯作者：
Lack, Gideon
影响因子：
2.9
作者：
Denning, David W.;Pleuvry, Alex;Cole, Donald C.
通讯作者：
Cole, Donald C.
影响因子：
6.1
作者：
Corren, J.;Casale, T. B.;Jimenez, P.
通讯作者：
Jimenez, P.
影响因子：
14.2
作者：
Beck, LA;Marcotte, GV;Saini, S
通讯作者：
Saini, S